Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female older adults greater than or equal to 50 years of age~Exclusion Criteria:~* Any adult with a history of previous hepatitis B infection~* A history of vaccination with any hepatitis B vaccine~* Recent (\<72 hours) history of febrile illness (oral temperature =37.8ºC/=100.0ºF)~* Known or suspected hypersensitivity to any component of RECOMBIVAX HB™ or ENGERIX-B™ (e.g., aluminum, yeast)~* Recent administration (within 3 months prior to first injection with the study vaccine) of hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product~* Receipt of licensed inactivated vaccines within 14 days prior to first injection with the study vaccine~* Receipt of licensed live virus vaccines within the 30 days prior to injection with the study vaccine~* Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine~* Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids). Does not include topical and inhaled steroids~* Pregnant women, nursing mothers, and women planning to become pregnant within the study period~* Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): RECOMBIVAX HB™
- 2 (Type: EXPERIMENTAL): Modified Process Hepatitis B Vaccine
- 3 (Type: ACTIVE_COMPARATOR): ENGERIX-B™

Based on this trial design, predict the completion outcome and termination type (if applicable).